Inventor
GEURTSEN JEROEN
NL12 patents
⚠️ This page may combine multiple inventors who share the name “GEURTSEN JEROEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICALS INC
11 patentsUS11446370B2Sep 20, 2022
Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
JANSSEN PHARMACEUTICALS INC6 citations81
US11421003B2Aug 23, 2022
FimH mutant, compositions therewith and use thereof
JANSSEN PHARMACEUTICALS INC4 citations79
US12012435B2Jun 18, 2024
FimH mutant, compositions therewith and use thereof
JANSSEN PHARMACEUTICALS INC2 citations68
US11725028B2Aug 15, 2023
FimH mutants, compositions therewith and use thereof
JANSSEN PHARMACEUTICALS INC3 citations68
US12233121B2Feb 25, 2025
Methods of producing bioconjugates of E. coli O-antigen polysaccharides, compositions thereof, and methods of use thereof
JANSSEN PHARMACEUTICALS INC0 citations58
US11931405B2Mar 19, 2024
Bioconjugates of E. coli O-antigen polysaccharides, methods of production thereof, and methods of use thereof
JANSSEN PHARMACEUTICALS INC1 citations58
US11491220B2Nov 8, 2022
Methods of producing bioconjugates of E. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
JANSSEN PHARMACEUTICALS INC0 citations58
US12428449B2Sep 30, 2025
FimH mutant, compositions therewith and use thereof
JANSSEN PHARMACEUTICALS INC0 citations56
US12297238B2May 13, 2025
FimH mutants, compositions therewith and use thereof
JANSSEN PHARMACEUTICALS INC0 citations56
US12290563B2May 6, 2025
Production of E. coli 018 bioconjugates
JANSSEN PHARMACEUTICALS INC0 citations47
US12233118B2Feb 25, 2025
Multivalent vaccine compositions and uses thereof
JANSSEN PHARMACEUTICALS INC0 citations41